Rapid Dose Therapeutics Corp. (RDTCF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Rapid Dose Therapeutics Corp. (RDTCF) trades at $0.085 with AI Score 57/100 (Grade B). Rapid Dose Therapeutics Corp. focuses on developing and commercializing innovative drug delivery technologies, primarily through its QuickStrip oral fast-dissolving system. Market cap: $11.5M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for RDTCF: RDTCF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RDTCF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
RDTCF: the 3 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Rapid Dose Therapeutics Corp. (RDTCF) Healthcare & Pipeline Overview
Rapid Dose Therapeutics Corp. is a Canadian life sciences company specializing in oral fast-dissolving drug delivery systems, including its QuickStrip technology, targeting pharmaceuticals, nutraceuticals, and cannabis industries; it faces competition in a rapidly evolving market while focusing on product innovation and strategic partnerships.
What Is the Investment Thesis for RDTCF?
Rapid Dose Therapeutics Corp. presents a speculative investment opportunity within the biotechnology sector, driven by its QuickStrip drug delivery technology. The company's potential lies in its ability to improve drug bioavailability and patient compliance through its innovative oral dissolving strips. A key value driver is the successful commercialization of QuickStrip across various applications, including pharmaceuticals, nutraceuticals, and cannabis. However, the company's negative profit margin of -157.2% and OTC market listing highlight significant risks. The success of RDTCF hinges on securing partnerships, navigating regulatory hurdles, and achieving profitability. Investors should carefully consider the company's financial stability and competitive landscape before investing.
Based on FMP financials and quantitative analysis
RDTCF Key Highlights
Market capitalization of $11.5M indicates a micro-cap company with high growth potential but also higher risk.
- Negative P/E ratio of -3.31 reflects current unprofitability, suggesting the company is in a growth phase or facing financial challenges.
- Gross margin of 29.8% indicates the company retains a portion of revenue after accounting for the cost of goods sold, but further operational efficiencies may be needed.
- Beta of -0.91 suggests the stock price is negatively correlated with the market, potentially offering diversification benefits but also indicating unique company-specific risks.
- The company's focus on QuickStrip technology for drug delivery positions it in a niche market with potential for growth in the pharmaceutical and nutraceutical sectors.
Who Are RDTCF's Competitors?
RDTCF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMHV American Hemp Ventures, Inc. | $0.98 | +0.00% | $16.5M | 46 |
| CRPOF Ceapro Inc. | $0.17 | -13.04% | $13.3M | 46 |
| EIGRQ Eiger BioPharmaceuticals, Inc. | $8.50 | +6.25% | $12.6M | 54 |
| LVCLY Living Cell Technologies Limited | $0.03 | +24.39% | $11.4M | 45 |
| MNNDF Nurosene Health Inc. | $0.33 | -8.71% | $14.3M | 46 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RDTCF's Key Strengths?
Innovative QuickStrip drug delivery technology.
- Research partnership with McMaster University.
- Expertise in product innovation and consultation services.
- Focus on oral fast-dissolving drug delivery systems.
What Are RDTCF's Weaknesses?
Negative profit margin and limited financial resources.
- OTC market listing indicates higher risk and lower liquidity.
- Dependence on strategic partnerships for commercialization.
- Limited market share and brand recognition.
What Could Drive RDTCF Stock Higher?
Potential regulatory approvals for QuickStrip-based products in various markets.
- Expansion of strategic partnerships with pharmaceutical, nutraceutical, and cannabis companies.
- Positive results from research and development activities, including the collaboration with McMaster University.
- Potential for new product launches incorporating QuickStrip technology.
- Expansion into new geographic markets.
What Are the Key Risks for RDTCF?
Financial-distress signal — its Altman Z-Score of -25.51 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Intense competition from established pharmaceutical and nutraceutical companies.
- Stringent regulatory requirements and approval processes.
- Dependence on strategic partnerships for commercialization.
- Negative profit margin and limited financial resources.
- OTC market listing indicates higher risk and lower liquidity.
What Are the Growth Opportunities for RDTCF?
- Expansion into the pharmaceutical market represents a significant growth opportunity for Rapid Dose Therapeutics. By partnering with pharmaceutical companies to incorporate QuickStrip technology into existing or new drug formulations, RDTCF can tap into a large and established market. The global pharmaceutical market is valued at over $1 trillion, offering substantial revenue potential for RDTCF if it can secure regulatory approvals and commercial partnerships. Timeline: Ongoing.
- The nutraceutical market offers another avenue for growth. QuickStrip can be used to deliver vitamins, supplements, and other nutraceutical products in a convenient and effective manner. The global nutraceutical market is projected to reach $400 billion by 2030, presenting a significant opportunity for RDTCF to expand its product offerings and market reach. Timeline: Ongoing.
- The cannabis healthcare sector is a rapidly growing market. QuickStrip can be used to deliver cannabis-based medications and products in a discreet and controlled manner. As regulations surrounding cannabis evolve, RDTCF can capitalize on the increasing demand for innovative delivery methods. The global cannabis market is expected to reach $55 billion by 2026. Timeline: Ongoing.
- Strategic partnerships with research institutions and universities, such as the collaboration with McMaster University, can drive innovation and product development. These partnerships can lead to the discovery of new applications for QuickStrip technology and the development of novel drug delivery systems. Timeline: Ongoing.
- International expansion represents a long-term growth opportunity for Rapid Dose Therapeutics. By expanding its operations into new geographic markets, RDTCF can increase its customer base and revenue streams. This expansion may involve establishing partnerships with local distributors or setting up its own manufacturing facilities in key markets. Timeline: Future.
What Are RDTCF's Competitive Advantages?
- Proprietary QuickStrip technology offers a unique drug delivery method.
- Research partnership with McMaster University provides access to cutting-edge research and development.
- Focus on oral fast-dissolving drug delivery systems differentiates it from traditional drug delivery methods.
- Expertise in product innovation, production, and consultation services offers a comprehensive solution for clients.
What Does RDTCF Do?
Rapid Dose Therapeutics Corp., established to revolutionize drug delivery, is a life sciences company headquartered in Burlington, Canada. The company's core technology, QuickStrip/PharmaStrip, is an oral fast-dissolving drug delivery system designed to rapidly release active ingredients into the bloodstream. This technology is applicable to a wide range of substances, including pharmaceuticals, emulsified oils, and over-the-counter medicines. Beyond its core QuickStrip technology, Rapid Dose Therapeutics offers product innovation, production, and consultation services to the nutraceutical, cannabis healthcare, and pharmaceutical manufacturing industries. This multifaceted approach allows the company to generate revenue through various streams, including licensing, manufacturing, and service agreements. Rapid Dose Therapeutics also engages in research and development activities, including a research partnership program with McMaster University. This collaboration focuses on developing biopolymer compositions to enhance drug delivery performance in oral dissolvable thin films and exploring orally delivered vaccine candidates, including for COVID-19. The company's strategic focus on innovation and partnerships positions it to capitalize on emerging trends in the drug delivery market and expand its product portfolio.
What Products and Services Does RDTCF Offer?
- Develops and commercializes QuickStrip, an oral fast-dissolving drug delivery system.
- Provides product innovation and consultation services to the nutraceutical industry.
- Offers production services to the cannabis healthcare industry.
- Provides drug delivery technologies designed to enhance outcomes and quality of lives.
- Partners with McMaster University for research and development of biopolymer compositions.
- Aims to develop orally delivered vaccine candidates.
How Does RDTCF Make Money?
- Generates revenue through the sale and licensing of QuickStrip technology.
- Provides product innovation, production, and consultation services to various industries.
- Forms strategic partnerships with pharmaceutical, nutraceutical, and cannabis companies.
- Conducts research and development activities to expand its product portfolio.
What Industry Does RDTCF Operate In?
Rapid Dose Therapeutics Corp. operates within the biotechnology industry, which is characterized by rapid innovation, intense competition, and stringent regulatory requirements. The drug delivery market is experiencing growth, driven by the demand for more effective and patient-friendly drug formulations. Competitors include companies like American Health Ventures (AMHV), and Liquid Cell (LVCLY), all vying for market share in the oral drug delivery space. RDTCF's success depends on its ability to differentiate its QuickStrip technology and secure strategic partnerships.
Who Are RDTCF's Key Customers?
- Pharmaceutical companies seeking innovative drug delivery systems.
- Nutraceutical companies looking to enhance product efficacy and convenience.
- Cannabis healthcare companies seeking discreet and controlled delivery methods.
- Consumers seeking convenient and effective ways to take medications and supplements.
Financial Health
Rapid Dose Therapeutics Corp.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -25.51 places it in the distress zone, a signal of elevated financial risk.
Quarterly Financial Performance: Rapid Dose Therapeutics Corp.
Revenue for Rapid Dose Therapeutics Corp. came in at $585K during Q2 2026, a 11.4% contraction versus the preceding quarter. The company recorded a net loss of $504K, with diluted EPS of $-0.00. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, RDTCF averaged $-0.01 in diluted EPS.
RDTCF Valuation & Market Position
With a $11.5M market cap, Rapid Dose Therapeutics Corp. sits in the micro-cap segment of the market. Relative to its peer group, RDTCF's quantitative score of 57/100 is roughly in line with the peer average of 47/100.
Key Financial Metrics
Return on equity for Rapid Dose Therapeutics Corp. stands at 54.2%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -2.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.04 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -23.9%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
Rapid Dose Therapeutics Corp. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Burlington, CA. The company is led by CEO Mark Andrew Upsdell. RDTCF has traded publicly since 2019.
RDTCF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Innovative QuickStrip drug delivery technology.
- Research partnership with McMaster University.
- Expertise in product innovation and consultation services.
- Focus on oral fast-dissolving drug delivery systems.
Bear Case
- Negative profit margin and limited financial resources.
- OTC market listing indicates higher risk and lower liquidity.
- Dependence on strategic partnerships for commercialization.
- Limited market share and brand recognition.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $584,894 | -$504,018 | -$0.0037 |
| Q1 2026 | $660,515 | -$700,000 | -$0.01 |
| Q4 2025 | $656,372 | -$1M | -$0.01 |
| Q3 2025 | $672,921 | -$825,474 | -$0.01 |
Based on FMP financials and quantitative analysis
RDTCF Latest News
No recent news available for RDTCF.
RDTCF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RDTCF.
Price Targets
Wall Street price target analysis for RDTCF.
RDTCF MoonshotScore
What does this score mean?
The MoonshotScore rates RDTCF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Mark Andrew Upsdell
CEO
Mark Andrew Upsdell serves as the CEO of Rapid Dose Therapeutics Corp. His background includes experience in the pharmaceutical and healthcare industries, with a focus on business development and strategic partnerships. He has held various leadership positions in companies focused on drug delivery and healthcare innovation. Upsdell's expertise lies in driving growth through strategic alliances and commercializing innovative technologies.
Track Record: Under Mark Andrew Upsdell's leadership, Rapid Dose Therapeutics Corp. has focused on expanding the applications of its QuickStrip technology and securing partnerships with pharmaceutical and nutraceutical companies. He has overseen the company's research and development efforts, including the collaboration with McMaster University. His strategic decisions have aimed to position RDTCF as a leader in oral fast-dissolving drug delivery systems.
RDTCF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Rapid Dose Therapeutics Corp. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial information available to the public, and trading activity may be thin. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Thin trading volume and wide bid-ask spreads.
- Potential for price manipulation and fraud.
- Lack of regulatory oversight and investor protection.
- Higher risk of delisting or going out of business.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Review the company's legal and regulatory compliance.
- Evaluate the company's capital structure and debt levels.
- Monitor trading volume and price activity for signs of manipulation.
- Consult with a qualified financial advisor before investing.
- Existence of a functional website and investor relations materials.
- Partnership with McMaster University for research and development.
- Development of QuickStrip technology with potential applications.
- Active engagement with the investor community through press releases and public statements.
- CEO with prior experience in the pharmaceutical and healthcare industries.
What Investors Ask About Rapid Dose Therapeutics Corp. (RDTCF) — Healthcare
What does the AI Score mean for RDTCF?
RDTCF holds an AI Score of 57/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Rapid Dose Therapeutics Corp. focuses on developing and commercializing innovative drug delivery technologies, primarily through its QuickStrip oral fast-dissolving system. The company aims …
What does Rapid Dose Therapeutics Corp. do?
Rapid Dose Therapeutics Corp. is a life sciences company focused on developing and commercializing innovative drug delivery technologies. Its core product is QuickStrip, an oral fast-dissolving strip designed to deliver active ingredients directly into the bloodstream. The company offers product innovation, production, and consultation services to the nutraceutical, cannabis healthcare, and pharmaceutical manufacturing industries, aiming to improve drug efficacy and patient experience through its advanced delivery systems.
What do analysts say about RDTCF stock?
There is currently no available analyst coverage or consensus for RDTCF stock due to its OTC listing and small market capitalization. Investment decisions should be based on individual due diligence and risk tolerance. Key valuation metrics, such as revenue growth and profitability, should be carefully considered. The company's growth potential hinges on the successful commercialization of QuickStrip and strategic partnerships.
What are the main risks for RDTCF?
The main risks for Rapid Dose Therapeutics Corp. include its negative profit margin, limited financial resources, and OTC market listing, which indicates higher risk and lower liquidity. The company also faces intense competition from established pharmaceutical and nutraceutical companies, as well as stringent regulatory requirements and approval processes. Dependence on strategic partnerships for commercialization poses another risk, as the success of RDTCF depends on securing and maintaining these alliances.
What are the key factors to evaluate for RDTCF?
Rapid Dose Therapeutics Corp. (RDTCF) holds an AI score of 57/100 (moderate). presents a speculative investment opportunity within the biotechnology sector, driven by its QuickStrip drug delivery technology. Not financial advice.
How frequently does RDTCF data refresh on this page?
RDTCF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven RDTCF's recent stock price performance?
Rapid Dose Therapeutics Corp. (RDTCF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative QuickStrip drug delivery technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RDTCF overvalued or undervalued right now?
Rapid Dose Therapeutics Corp. (RDTCF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research RDTCF before investing?
Before investing in Rapid Dose Therapeutics Corp. (RDTCF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available sources and may be subject to change.
- OTC market stocks carry higher risks than exchange-listed stocks.
- Financial data may be limited or unaudited.